Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study
Brief: Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Brief: Kineta Announces Exclusivity And Right Of First Offer Agreement For Its Vista Blocking Antibody With Tuhura Biosciences
Brief: Kineta Inc On May 23, Got Notice From Nasdaq That It No Longer Complies With Requirement Under Nasdaq Listing Rule 5550(B)(1)
Brief: Kineta Says Co Entered Into A Settlement Agreement And Mutual Release By And Between Company And RLB Holdings Connecticut, Llc
Kineta jumps on positive early-stage tumor treatment trial
Brief: Kineta Reports Response Data Of Ongoing Vista-101 Clinical Trial At AACR 2024
Kineta Inc to explore strategic alternatives, shares fall
Brief: Kineta Announces Restructuring And Exploration Of Strategic Alternatives
Brief: Kineta Says Co Intends To Explore Strategic Alternatives
Brief: Kineta entered into an option and license agreement with GigaGen
Brief: Kineta Publishes Preclinical Data Demonstrating The Potential Of Anti-VISTA Antibody KVA12123
Brief: Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123
Brief: Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA(pembrolizumab)
Brief: Kineta, Inc. Announces Closing Of $3 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Brief: Kineta Presents New Preclinical Data On Lead Anti-Cd27 Agonist Antibody